Biogen Inc

Company Profile

• Business description

  Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

• Contact

  225 Binney Street
  CambridgeMA02142
  USA

  T: +1 617 679-2000

  E: [email protected]

  https://www.biogen.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Drug Manufacturers - General

  Fiscal Year End

  31 December 2026

  Employees

  7,500